Interest Cost Reduction Deleveraging
Expected: CurrentHIGH confidence
What: Interest Cost: ₹0.01 Cr
Impact: PAT growth of 30.5%
Venus Remedies Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +38.4%Average9w StreakRe-Entry
In , Venus Remedies Ltd (Pharmaceuticals - I V Fluids) is outperforming Nifty 500 with +38.4% relative strength. Fundamentals: Average. On a 9-week streak.
Venus Remedies Ltd Key Facts
- PE Ratio
- 17.6x
- Market Cap
- ₹1,346 Cr
- PAT Growth YoY
- +30%
- Revenue Growth YoY
- +2%
- OPM
- 21.0%
- RS vs Nifty 500
- +38.4%
PE: Early ExpansionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
📊Debt increased 600% YoY — leverage rising
🌐FII stake increased 0.7% this quarter
💰Trading 38% below estimated fair value
Earnings Acceleration Triggers
1. Interest Cost Reduction Deleveraging
CurrentHIGH
2. Regulatory Approval Or License Win
OngoingMEDIUM
Key Risks
1. Middle East conflict impacting supply chains and global coordination
MEDIUMSector-Specific Signals
Global Marketing Authorizations1040+Not Given
Total Patents135+Not Given
PLI Scheme Disbursement₹11.77 CrNot Given
Key Numbers
PAT Growth YoY
+30%
Stable
Revenue YoY
+2%
Stable
Operating Margin
21.0%
+1100 bps YoY
PE Ratio
17.6
Current Price
₹1,007
Fundamental Score
58/100
Average
3Y PAT CAGR
+3%
Market Cap
1.3K Cr
Valuation
Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Venus Remedies Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
Regulatory Approval Or License Win
Expected: OngoingMEDIUM confidence
What: Marketing Authorizations: 1040+
Impact: Global expansion
What Are the Key Risks for Venus Remedies Ltd?
Earnings deceleration risks from management commentary
Middle East conflict impacting supply chains and global coordination
MEDIUMTrigger: Middle East conflict impacting supply chains and global coordination.
Impact: PAT impact: Not Given
Management view: Monitoring monetary transitions and global coordination.
Monitor: geopolitical
What Did Venus Remedies Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹180.26 Cr
YoY +2.12%QoQ -6.48%
Revenue saw a marginal year-on-year increase but declined sequentially due to quarterly volatility in injectable formulations.
EBITDA
₹37.52 Cr
YoY +108.21%Margin 20.81%
EBITDA growth significantly outpaced revenue due to sharp reductions in total operating expenses.
PAT
₹25.58 Cr
YoY +30.51%QoQ +27.07%
PAT growth was driven by operational efficiency and a reduction in interest costs to negligible levels.
Other Highlights
• Total expenses fell 11.1% QoQ to ₹149.31 Cr
• Nine-month PAT surged 127.20% to ₹55.31 Cr
• Received ₹11.77 Cr incentive under PLI scheme
What Sector Metrics Matter for Venus Remedies Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Global Marketing Authorizations
1040+
YoY Not GivenQoQ Not Given
Why: Focus on research-led global expansion in critical care and oncology.
Total Patents
135+
YoY Not GivenQoQ Not Given
Why: Strategic shift to a research-driven organization focusing on AMR and oncology.
PLI Scheme Disbursement
₹11.77 Cr
YoY Not GivenQoQ Not Given
Why: Participation in government initiatives to strengthen domestic healthcare manufacturing.
What Is Venus Remedies Ltd's Management Guidance?
Forward-looking targets from management for FY26
Revenue Outlook
₹770 Cr
Volume
Robotic line capacity of 20 million units
Management Tone: BULLISH
How Fast Is Venus Remedies Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +2% | +2% | Stable |
| PAT (Net Profit) | +30% | +3% | Stable |
| OPM | 21.0% | +1100 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Frequently Asked Questions: Venus Remedies Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Venus Remedies Ltd's latest quarterly results?
Venus Remedies Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +30.0% (stable)
- Revenue Growth YoY: +1.7%
- Operating Margin: 21.0% (volatile)
Is Venus Remedies Ltd's profit growing or declining?
Venus Remedies Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +30.0% (latest quarter)
- PAT Growth QoQ: +30.0% (sequential)
- 3-Year PAT CAGR: +3.1%
- Trend: Stable — consistent growth pattern
What is Venus Remedies Ltd's revenue growth trend?
Venus Remedies Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +1.7%
- Revenue Growth QoQ: -6.7% (sequential)
- 3-Year Revenue CAGR: +2.4%
How is Venus Remedies Ltd's operating margin trending?
Venus Remedies Ltd's operating margin is volatile.
- Current OPM: 21.0%
- OPM Change YoY: +11.0% basis points
- OPM Change QoQ: +5.0% basis points
What is Venus Remedies Ltd's 3-year profit and revenue CAGR?
Venus Remedies Ltd's long-term compounding rates
- 3-Year Profit CAGR: +3.1%
- 3-Year Revenue CAGR: +2.4%
Is Venus Remedies Ltd's growth accelerating or decelerating?
Venus Remedies Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -70.0% bps
- Sequential Acceleration: -20.0% bps
What is Venus Remedies Ltd's trailing twelve month (TTM) performance?
Venus Remedies Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹77 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹705 Cr
- TTM Revenue Growth: +8.3% YoY
- TTM Operating Margin: 16.0%
Is Venus Remedies Ltd overvalued or undervalued?
Venus Remedies Ltd appears undervalued based on our fair value analysis.
- Valuation Signal: Undervalued
- Current PE: 17.6x
- Price-to-Book: 2.3x
What is Venus Remedies Ltd's current PE ratio?
Venus Remedies Ltd's current PE ratio is 17.6x.
- Current PE: 17.6x
- Market Cap: 1.3K Cr
How does Venus Remedies Ltd's valuation compare to its history?
Venus Remedies Ltd's current PE is 17.6x.
- Current PE: 17.6x
- Valuation Assessment: Undervalued
What is Venus Remedies Ltd's price-to-book ratio?
Venus Remedies Ltd's price-to-book ratio is 2.3x.
- Price-to-Book (P/B): 2.3x
- Book Value per Share: ₹445
- Current Price: ₹1007
Is Venus Remedies Ltd a fundamentally strong company?
Venus Remedies Ltd is rated Average with a fundamental score of 58.2/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +1.7% (10% weight)
- PAT Growth YoY: +30.0% (10% weight)
- PAT Growth QoQ: +30.0% (10% weight)
- Margins stable (10% weight)
Is Venus Remedies Ltd debt free?
Venus Remedies Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹14 Cr
What is Venus Remedies Ltd's return on equity (ROE) and ROCE?
Venus Remedies Ltd's return ratios over recent years
- FY2023: ROCE 8.0%
- FY2024: ROCE 9.0%
- FY2025: ROCE 11.0%
Is Venus Remedies Ltd's cash flow positive?
Venus Remedies Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹86 Cr
- Free Cash Flow (FCF): ₹9 Cr
- CFO/PAT Ratio: 191% (strong cash conversion)
What is Venus Remedies Ltd's dividend yield?
Venus Remedies Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹1007
Who holds Venus Remedies Ltd shares — promoters, FII, DII?
Venus Remedies Ltd's shareholding pattern (Mar 2026)
- Promoters: 41.8%
- FII (Foreign): 2.8%
- DII (Domestic): 1.2%
- Public: 54.2%
Is promoter holding increasing or decreasing in Venus Remedies Ltd?
Venus Remedies Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 41.8% (Mar 2026)
- Previous Quarter: 41.8% (Dec 2025)
- Change: 0.00% (stable)
How long has Venus Remedies Ltd been outperforming Nifty 500?
Venus Remedies Ltd has been outperforming Nifty 500 for 9 consecutive weeks, indicating consistent outperformance.
Is Venus Remedies Ltd a new momentum entry or an established outperformer?
Venus Remedies Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Venus Remedies Ltd?
Venus Remedies Ltd has 2 key growth catalysts identified from recent earnings analysis
- Interest Cost Reduction Deleveraging — Debt-free status significantly protects bottom line from interest volatility.
- Regulatory Approval Or License Win — Broad authorization base enables rapid entry into diverse geographic markets.
What are the key risks in Venus Remedies Ltd?
Venus Remedies Ltd has 1 key risk worth monitoring
- [MEDIUM] Middle East conflict impacting supply chains and global coordination — Middle East conflict impacting supply chains and global coordination.
What is Venus Remedies Ltd's management guidance for growth?
Venus Remedies Ltd's management has provided the following forward guidance for FY26
- Revenue outlook: ₹770 Cr
- Margin outlook: Not Given
- Capex plan: Not Given for Infrastructure for quality and safety
- Management tone: bullish
What sector-specific metrics matter most for Venus Remedies Ltd?
Venus Remedies Ltd's most important sub-sector-specific KPIs from the latest concall
- Global Marketing Authorizations: 1040+ (YoY Not Given) (QoQ Not Given) — Focus on research-led global expansion in critical care and oncology.
- Total Patents: 135+ (YoY Not Given) (QoQ Not Given) — Strategic shift to a research-driven organization focusing on AMR and oncology.
- PLI Scheme Disbursement: ₹11.77 Cr (YoY Not Given) (QoQ Not Given) — Participation in government initiatives to strengthen domestic healthcare manufacturing.
Is Venus Remedies Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Venus Remedies Ltd may be worth studying
- Earnings growing at +30.0% YoY
- Valuation: appears undervalued
- Cash flow is positive — CFO ₹86 Cr
What is the investment thesis for Venus Remedies Ltd?
Venus Remedies Ltd investment thesis summary:
Research Signals (Bull Case)
- Appears undervalued
- Growth catalyst: Interest Cost Reduction Deleveraging
Risk Factors (Bear Case)
- Key risk: Middle East conflict impacting supply chains and global coordination
What is the future outlook for Venus Remedies Ltd?
Venus Remedies Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Undervalued
- Key Catalyst: Interest Cost Reduction Deleveraging
- Key Risk: Middle East conflict impacting supply chains and global coordination
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.